Human Tissue and Genomics Core

核心B的主要目标是为单个项目提供肠道组织、分离的细胞群和 来自临床特征的IBD患者和健康对照的功能基因组信息。这个核心将 克服广泛承认的动物模型使用障碍-指导动物研究以解决 可以直接翻译成人类IBD的问题。数据和组织库与新技术 通过这个核心的开发将使研究人员有机会将分子发现与 人类疾病的典范物种。核心B将利用北卡罗来纳大学现有的实质性资源和专门知识。 在获取和处理外科手术切除和肠道活组织检查方面有一个既定的基础设施。 核心B的“组织”部分将处理和提供冷冻的肠道组织；RNA和蛋白质提取物 从肠道组织中，确定疾病表型的临床信息，并应 寄主，孤立的肠道细胞群。在需要的情况下，核心将能够提供匹配的 外周血单核细胞血清及DNA与免疫表型、临床相关性的研究 有遗传背景的表型。对人类IBD的分子基础的了解还远远不够 已实现。高通量分析，允许识别异质性中的基因调控网络 像IBD这样的疾病对于阐明IBD的致病机制以及对 开发诊断工具和创新疗法。核心B的“基因组学”部分将使用 染色质状态(FIRE和CHIP)和基因表达(RNA)的高通量互补分析 从分离的单个细胞(小鼠和人)和临床表型配对结合的深 测序。每个项目都通过集中的数据处理和分析获利，从而增加了可行性和 提高效率，降低每个计划项目调查员的成本，并限制可能发生的差异 技术错误。此外，核心B利用并建立在财务承诺和技术承诺的基础上 美国国立卫生研究院(ENCODE，1000基因组和HapMap项目)和卡罗莱纳中心已经取得的专业知识 为了基因组科学。核心B生成的数据将允许每个调查员研究主动监管 基因组中的元素在细节层面上尚未被执行。

The primary goal of Core B is to provide individual projects with intestinal tissue, isolated cell populations, and functional genomic information from clinically characterized IBD patients and healthy controls. This core will overcome a widely acknowledged roadblock in the use of animal models - direcfing animal research to address questions that will be directly translatable to human IBD. The data and tissue banks and novel technologies developed through this core will allow investigators the opportunity to correlate molecular findings across model species to human diseases. Core B will leverage substanfial existing resources and expertise at UNC. There is an established infrastructure for obtaining and processing surgical resecfions and intestinal biopsies. The "Tissue" component of Core B will process and provide frozen intestinal tissue; RNA and protein extracts from intestinal tissue, deidentified clinical information on disease phenotype, and at the request of invesfigators, isolated intestinal cell populations. Where required, the core will be able to provide matched serum in peripheral blood mononuclear cell populafions as well as DNA to correlate immunophenotype, clinical phenotype with genetic background. Understanding the molecular basis of human IBD is far from being achieved. High throughput assays that permit the identification of gene regulatory networks in a heterogeneous disease like IBD is of paramount importance to elucidate the pathogenic mechanisms of IBD and for the development of diagnostic tools and of innovative therapeutics. The "Genomics" component of Core B will use complementary high throughput assays of chromatin status (FAIRE, and ChIP) and gene expression (RNA) from isolated single cells (murine and human), and clinically phenotyped pafients combined with deep sequencing. Each Project profits by centralized data processing and analysis that increases feasibility and efficiency, decreases costs for each Program Project investigator and limits variations that may occur from technical error. Furthermore, Core B capitalizes and builds on the financial commitments and technical expertise already made by the NIH (ENCODE, 1000 genomes, and HapMap projects) and the Carolina Center for Genome Sciences. Data generated by Core B will allow each investigator to study active regulatory elements in the genome at a level of detail yet to be performed.